Virax to acquire advanced cancer platform from Yale Uni
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Virax Option to Acquire Exclusive Worldwide Licence
- Virax Holdings Appendix 4E and 2014 Financial Report
- VHL completes Pathway acquisiton, appoints new director
- Disclosure Document
- Co-X-Gene Development Pipeline
Later from Prescient Therapeutics
- Dutchess Continuous Investment Agreement - 10 January 2012
- Rights Offer - 19 July 2011
- Suspension from Official Quotation - VHLG
- TG1042 Batch Manufacturing Completed - 26 July 2011
- TG1042 Update - Melanoma
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics